Home › DanDrit Biotech A/S Signs Agreement to Commence Clinical Trials of MelCancerVac
 

Keywords :   


DanDrit Biotech A/S Signs Agreement to Commence Clinical Trials of MelCancerVac

2014-10-01 11:13:37| Biotech - Topix.net

DanDrit Biotech A/S , the subsidiary of DanDrit Biotech USA, Inc. , a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST - National Institute for Cancer Research known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital is principal investigator of the randomized multicenter study.

Tags: agreement signs clinical trials

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.04PPG Earns EcoVadis Gold Rating for Sustainability Practices
26.04Colombia puts restrictions on U.S. beef due to H5N1 in dairy cattle
26.04Techtextil Reports 29% Visitor Increase
26.04Mark Andy hosts digital event, ProMach details acquisition and more
26.04L Catterton Acquires Majority Stake in Kiko Milano from Percassi Family
26.04ROTOCON reveals 2024 Wine Label Design Award recipients
26.04X Corp confirms intention to launch app for Smart TVs
26.04Giant 3D printer that can build a house goes live
More »